Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives

被引:25
|
作者
Shchelochkov, Oleg A. [1 ]
Dickinson, Klara [2 ]
Scharschmidt, Bruce F. [3 ]
Lee, Brendan [4 ]
Marino, Miguel [5 ]
Le Mons, Cynthia [6 ]
机构
[1] Univ Iowa Hosp & Clin, Stead Dept Pediat, Iowa City, IA 52242 USA
[2] Anthera Pharmaceut, Hayward, CA USA
[3] Horizon Therapeut, Lake Forest, IL USA
[4] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA
[5] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[6] Natl Urea Cycle Disorders Fdn, 75 S Grand Ave, Pasadena, CA 91105 USA
关键词
D O I
10.1016/j.ymgmr.2016.07.003
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Patients and families living with metabolic disorders face challenging dietary and drug treatment regimens. On the hypothesis that poor palatability, volume and frequency of drug/formula administration contribute to treatment non-adherence and hyperammonemic episodes, a survey was conducted of patient, caregiver (CG) and physician perspectives on treatments used in urea cycle disorders (UCD). Methods: A paper and online survey assessed experience with UCD medications, medical foods and dietary supplements. Results: 25 physicians, 52 adult patients and 114 CG responded. In 2009, the most common UCD-specific intervention reported by patients included sodium phenylbutyrate (60%), followed by L-citrulline (46%), amino acid medical foods (15%), L-arginine preparations (18%), and sodium benzoate (8%). Only 36% of patients reported experiencing no hyperammonemic episodes in the last 2 years. The most commonly reported cause of hyperammonemic episodes was infection or other acute illnesses, followed by dietary indiscretion, side effects of medications, and drug non-adherence. Most patients, caregivers and physicians (N75%) ranked nitrogen-scavenging medications, L-citrulline, L-arginine, and medical foods as "effective" or "very effective." Nonadherence was common (e.g. 18% of patients admitted to missing sodium phenylbutyrate "at least once a week" and "at least one a day"). Barriers to adherence included taste of medications, frequency of drug administration, number of pills, difficulty swallowing pills, side effects, forgetting to take medications, and high cost. Strategies to mitigate the gastrointestinal side effects of medications included the use of gastric tubes and acid reflux medications. Physicians indicated that 25% and 33% of pediatric and adult patients, respectively, were given less than the recommended dose of sodium phenylbutyrate due to concerns of tolerance, administration, and cost. Conclusions: Despite positive views of their effectiveness, respondents found medications, medical foods and dietary supplements difficult to take and viewed adherence as inadequate, thus contributing to hyperammonemic episodes. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:43 / 47
页数:5
相关论文
共 50 条
  • [1] ASSESSMENT OF BARRIERS TO DRUG ADHERENCE IN THE TREATMENT OF UREA CYCLE DISORDERS IN NORTH AMERICA
    Shchelochkov, Oleg A.
    Lee, Brendan H.
    Scharschmidt, Bruce
    Dickinson, Klara
    Herberich, Ellen
    Hawkins, Scott
    Smith, Jasmin
    Le Mons, Cynthia
    [J]. MOLECULAR GENETICS AND METABOLISM, 2014, 111 (03) : 280 - 280
  • [2] Assessment of barriers to drug adherence in the treatment of urea cycle disorders in North America
    Shchelochkov, Oleg A.
    Lee, Brendan H.
    Scharschmidt, Bruce F.
    Dickinson, Klara A.
    Herberich, Ellen
    Hawkins, Scott
    Smith, Jasmin
    Le Mons, Cynthia
    [J]. CLINICAL BIOCHEMISTRY, 2014, 47 (15) : 153 - 153
  • [3] Comparative Assessment of Patient and Provider Perspectives on the Impact of Sociobehavioral Factors on Glaucoma Treatment Adherence
    Poleon, Shervonne
    Racette, Lyne
    Fifolt, Matthew
    Schoenberger-Godwin, Yu-Mei
    Twa, Michael D.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [4] Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: patient perspectives
    Pena-Quintana, Luis
    Llarena, Marta
    Reyes-Suarez, Desiderio
    Aldamiz-Echevarria, Luis
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 1489 - 1496
  • [5] Barriers to Adherence to Antiretroviral Treatment The Perspectives of Patient Advocates
    Kagee, Ashraf
    Delport, Tracey
    [J]. JOURNAL OF HEALTH PSYCHOLOGY, 2010, 15 (07) : 1001 - 1011
  • [6] Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence
    Margo E. Godersky
    Andrew J. Saxon
    Joseph O. Merrill
    Jeffrey H. Samet
    Jane M. Simoni
    Judith I. Tsui
    [J]. Addiction Science & Clinical Practice, 14
  • [7] Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence
    Godersky, Margo E.
    Saxon, Andrew J.
    Merrill, Joseph O.
    Samet, Jeffrey H.
    Simoni, Jane M.
    Tsui, Judith, I
    [J]. ADDICTION SCIENCE & CLINICAL PRACTICE, 2019, 14 (1) : 11
  • [8] Barriers and enablers to adherence to anticoagulation in heart failure with atrial fibrillation: patient and provider perspectives
    Ferguson, Caleb
    Inglis, Sally C.
    Newton, Phillip J.
    Middleton, Sandy
    Macdonald, Peter S.
    Davidson, Patricia M.
    [J]. JOURNAL OF CLINICAL NURSING, 2017, 26 (23-24) : 4325 - 4334
  • [9] Adolescent, caregiver and provider perspectives on tuberculosis treatment adherence: a qualitative study from Lima, Peru
    Chiang, Silvia S.
    Senador, Liz
    Altamirano, Elmer
    Wong, Milagros
    Beckhorn, Catherine B.
    Roche, Stephanie
    Coit, Julia
    Rapoport, Victoria Elena Oliva
    Lecca, Leonid
    Galea, Jerome T.
    [J]. BMJ OPEN, 2023, 13 (05):
  • [10] Patient and Provider Perspectives on Glaucoma Treatment Adherence: A Delphi Study in Urban Alabama
    Poleon, Shervonne
    Racette, Lyne
    Fifolt, Matthew
    Schoenberger-Godwin, Yu-Mei
    Abu, Sampson Listowell
    Twa, Michael D.
    [J]. OPTOMETRY AND VISION SCIENCE, 2021, 98 (09) : 1085 - 1093